Ava Labs claims the New York Stock Exchange (NYSE) tested Avalanche blockchain technology for close to a year, highlighting a significant trial of public blockchain by a major traditional exchange. The testing was described as a technical evaluation without confirmed adoption or commercial agreement. Details on the specific technology tested, use cases, or outcomes remain undisclosed, and the NYSE has not publicly confirmed the claim. This trial reflects growing institutional interest in blockchain for settlement and asset servicing, though no deployment has been announced yet.
Ava Labs' claim about the NYSE testing Avalanche technology comes as 46 out of 50 major cryptocurrencies on Pluang rose today. For readers following the broader crypto market, here is Pluang's snapshot as of Sep 18, 2026 20:01 WIB: ONE (Harmony) surged 26.97% to Rp32 with a typical hold time of 154 days, UNI (Uniswap) gained 25.75% to Rp154.013 with 63% buy order activity, and COTI rose 14.15% to Rp383 with nearly balanced order activity.
Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...
Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...
Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...
Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...
Barclays lowered its price target for Lennar Corporation to $70 from a higher level, citing a 52% drop in Q3 net earnings to $284 million and an 8.6% revenue decline to $8.05 billion. The homebuilder faces headwinds from rising mortgage rates and wea...
